SecBot SecBot
PRESS-RELEASE ·Filed Mar 4, 2026

TCRX

TScan Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Investors should monitor upcoming Q2 2026 data readouts from Cohort C and the initiation of the pivotal trial for TSC-101, which could serve as major value inflection points. The expanded pipeline with FDA-cleared INDs increases long-term optionality. Reduced cash burn extends runway without near-term dilution risk.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK AT ENTRY AT T+60
Entry
$1.08
T+0 close · Mar 4, 2026 · via day close
Latest settled
0.00%
T+60 · $1.08
Vs SPY
−10.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 4 $1.08entry
  2. T+1 · 9mo ago +4.63%α +5.20% · $1.13
  3. T+5 · 8mo ago +6.48%α +7.81% · $1.15
  4. T+20 · 8mo ago −4.63%α −0.21% · $1.03
  5. T+60 · 6mo ago 0.00%α −10.09% · $1.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TScan Therapeutics reported financial results for Q4 and full-year 2025, highlighted by a 268% year-over-year increase in revenue to $10.3M driven by its Amgen collaboration, while R&D and G&A expenses declined QoQ. The company presented positive Phase 1 ALLOHA™ trial data showing improved survival trends and completed enrollment in Cohort C using its commercial-ready manufacturing process. FDA clearance of two new TCR-T candidates (TSC-102-A01/A03) expands its heme malignancy pipeline. Cash remains strong at $152.4M, sufficient to fund operations into H2 2027.

Key Financial Metrics

Revenue
$10.3M
+267.6% YoY
EPS
$-1.00

Key Facts

  • Q4 2025 revenue: $2.6M (vs. $0.7M in Q4 2024), full-year 2025 revenue: $10.3M (vs. $2.8M in 2024), driven by Amgen collaboration
  • Q4 2025 R&D expenses down 32% YoY to $20.0M; full-year R&D up slightly to $114.2M
  • Net loss narrowed to $23.0M in Q4 2025 (vs. $35.8M in Q4 2024)
  • Positive ALLOHA™ Phase 1 data: 100% (3/3) of TSC-101-treated patients relapse-free at 2-year follow-up vs. 25% (1/4) in control
  • FDA cleared INDs for TSC-102-A01 and TSC-102-A03 targeting CD45 in HLA-A*01:01 and A*03:01 patients
  • Cohort C enrollment completed with commercial-ready manufacturing; data expected Q2 2026
  • Cash and cash equivalents: $152.4M as of Dec 31, 2025, funding operations into H2 2027
  • Pivotal trial for TSC-101 to launch in Q2 2026

Financial Impact

Revenue increased by $7.5M YoY; net loss improved by $2.3M annually despite higher R&D spend; cash burn reduced significantly in Q4

revenuenet_losscash_positionoperating_expenses

Risk Factors

  • Clinical development risk: Early-phase data may not translate into pivotal trial success
  • High share count dilution: Pro forma shares exceed 129.9M due to pre-funded warrants
  • Reliance on Amgen collaboration for revenue; future payments dependent on milestones

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3249222

Track record

15 reports on TCRX

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
  2. Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
  3. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
  4. Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
  5. Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
  6. Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
  7. Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
  8. Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 6/10 No price data
  10. Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 4, 2026